Business Wire

First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

9.9.2024 15:00:00 EEST | Business Wire | Press release

Share

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the dosing of the first sentinel patients in its open-label, single-arm, multi-center Phase III study, NCT06129539 ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)’.Triptorelin is an established treatment for CPP as a 1-, 3- and 6-month formulation. This new phase III study evaluating the novel 12-month triptorelin formulation is being carried out in North and South America.

In pursuit of developing safe, effective, and convenient treatment options for patients, Debiopharm, is applying its expertise in extended-release formulations to achieve the first yearly injectable Gonadotropin-Releasing Hormone agonist (GnRHa). Reducing treatment burden while preserving triptorelin’s well-known efficacy and safety are key elements that Debiopharm is eager to assess through this study.

“It is always disheartening to see such young children burdened by the effects of central precocious puberty and the lifelong complications it may cause. We are thankful that treatments like triptorelin are already on the market, and that companies like Debiopharm continue to invest in lightening the patient care burden with formulations that reduce injection frequency,” expressed Prof. Fernando Cassorla, Principal Investigator, Pediatrics Department at the Hospital San Borja Arriarán in Santiago, Chile.

“As patients are at the center of all we do, we recognize that convenience matters. Reducing injection frequency to once a year can lower the burden for CPP patients and their caretakersby reducing children’s stress and improving overall compliance. We are enthusiastic about the first patients enrolled in this phase III trial that can bring both medical and practical advancements,” expressed Bertrand Ducrey, CEO of Debiopharm.

About Central Precocious Puberty

Central precocious puberty (CPP) occurs at an unusually early age, before 8 years of age in girls and before 9 years of age in boys [1-2]. It is characterized by a premature development of secondary sexual characteristics (e.g. breasts for girls and enlarged testicles for boys), accelerated growth, and bone maturation leading to reduced adult height. CPP is triggered by the early release of the gonadotropin-releasing hormone in the brain and premature activation of the hypothalamic-pituitary-gonadal axis. This early activation can be due to specific genetic alterations, central nervous system lesions, and social stressors but frequently has no identified etiology [3]. The approximative prevalence of CPP is 1 in 5,000-10,000 among Caucasians, more frequent in girls than in boys globally [4]. Precocious puberty may be associated with psychosocial difficulties and carries potential negative implications for long-term health including increased risk of metabolic complications, such as type 2 diabetes, weight gain, obesity, cardiovascular disease, as well as depression, and even premature death [5-10]. Early puberty has also been associated with an increased risk of breast cancer in women. In men, it may increase the risk of prostate cancer [11-13]. Since the early 1980s, Gonadotropin-Releasing Hormone agonists (GnRHa) such as triptorelin have been the standard of care for the treatment of CPP [14-16]. Treatment aims to preserve adult height and prevent social and psychological difficulties and the various potential consequences on long-term health. Currently, there are several different extended-release GnRHa formulations ranging from monthly injections to subcutaneous implants for annual use [17]. While the latter may have a longer duration of action, it requires yearly surgical positioning.

About Debio 4326

Debio 4326 is a unique injectable, biodegradable 12-month extended-release formulation of triptorelin designed to further reduce the frequency of injections and burden of administrations, particularly considering its intended use in a pediatric population. Based on favorable efficacy and safety data with the different triptorelin 1-, 3- and 6-month formulations, Debio 4326 aims to preserve efficacy while providing increased comfort, ensure long-term compliance, and reduce stress for children and their parents.

Debiopharm's commitment to patients

Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.

For more information, please visit www.debiopharm.com

We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

References

[1] Latronico AC, et al. Lancet Diabetes Endocrinol. 2016;4(3):265–274. [PubMed: 26852255]

[2] Sanctis V, et al. Acta biomedica: Atenei Parmensis. 2019 90 (3): 345-359.

[3] Maione L, et al. Clin Endocrinol (Oxf). 2021 Oct;95(4):542-555. doi: 10.1111/cen.14475. Epub 2021 Apr 20. PMID: 33797780; PMCID: PMC8586890

[4] National Organization for Rare Disorders (NORD) 2022

[5] Day FR, et al. 2015. Sci Rep, 5: 11208.

[6] Elks CE, et al. 2013. Diabetes Care, 36 (11): 3526-34.

[7] Prentice P, and Viner RM. 2013. Int J Obes (Lond), 37 (8): 1036-43

[8] Ong KK, et al. 2012. J Clin Endocrinol Metab, 97 (8): 2844-52.

[9] Hamlat EJ, et al. 2014. J Abnorm Child Psychol, 42 (4): 527-38.

[10] Charalampopoulos D, et al. 2014. Am J Epidemiol, 180 (1): 29-40.

[11] Day FR, et al. 2017. Nat Genet, 49 (6): 834-41.

[12] Bonilla C, et al. 2016. BMC Med, 14: 66.

[13] Bräuner EV, et al. 2020. JAMA Netw Open, 3 (10): e2015665

[14] Carel JC, et al. 2009. Pediatrics, 123 (4): e752-62.

[15] Bertelloni S, et al. 2015. Horm Res Paediatr, 84 (6): 396-400.

[16] Bangalore Krishna K, et al. 2019. Horm Res Paediatr, 91 (6): 357-72.

[17] Aguirre RS, Eugster EA. Best Pract Res Clin Endocrinol Metab. 2018;32(4):343–354.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909118587/en/

Contacts

Debiopharm Contact
Dawn Bonine
Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 16:30:00 EET | Press release

SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial networks. As demand grows for ubiquitous and resilient connectivity, Direct-to-Device services are expected to become an important c

From returns to restaurant bookings: Klarna’s AI assistant finds the best product & price, buys it for you, and you don’t pay until it arrives17.11.2026 16:26:00 EET | Press release

Klarna, the everyday finance network, today announced the Klarna AI-assistant, a personal assistant that handles shopping, returns, bookings, and everyday admin, so you don’t have to. Currently live with a small group of early users, the AI-assistant acts like a personal concierge, handling tasks on each customer’s behalf while keeping them firmly in control. Waitlist opens this week. The Klarna AI-assistant finds options and helps people decide, books anything from a table for two, to a babysitter, and keeps track of what they’re waiting for. It drafts email replies for approval, files receipts, and flags upcoming birthdays with gift ideas. This new AI-assistant builds on Klarna’s shopping assistant, a popular feature in its app. Klarna customers have spent more than $34 billion through the app’s built-in browser since 2020, a feature that lets you shop any website, including stores that don’t offer Klarna. “Back in 2015, we thought about the future of finance and imagined a day when

Impartner Launches MCP Server to Connect AI Assistants with Live PRM Data17.11.2026 16:19:00 EET | Press release

Impartner, the world's leading partner revenue orchestration platform, today announced the launch of Impartner MCP, enabling organizations to connect AI assistants directly to live partner relationship management (PRM) data. Powered by the Model Context Protocol (MCP), an open standard for connecting AI assistants with external systems and data sources, the integration makes Impartner PRM information accessible within supported AI environments without requiring users to navigate multiple reports and dashboards. With Impartner MCP, teams can ask natural-language questions about partner pipelines, deal registrations, account activity and program performance, receiving answers grounded in real-time operational data and governed by their existing access permissions. The integration works with supported AI assistants, including Claude, ChatGPT, Microsoft Copilot through Copilot Studio and Google Gemini Enterprise, as well as developer tools such as Claude Code. Through natural-language conv

Incode Launches Incode Know Your Agent to Anchor AI Agent Trust in Verified Human Identity17.11.2026 16:14:00 EET | Press release

Incode, the identity platform trusted by more than 800 organizations, including nine of the top 10 US banks, eight of the top nine US telcos, and four of the top five global marketplaces, today launched Incode Know Your Agent, which ties every AI agent to a verified person and to the mandate that person set. With Incode Know Your Agent, businesses can get access, control, and visibility over every agent that acts on behalf of their customers. AI agents already act on behalf of people in banking, commerce, and everyday services. A fraudster’s agent can arrive with the same valid credentials as a customer’s, making it impossible for a business to tell them apart. AI agents are creating a new kind of economy, and fraud is growing inside it. Nearly seven in 10 Americans (69%) say they would let a bank’s AI assistant complete at least one financial task for them,¹ and McKinsey estimates that AI agents could orchestrate $900 billion to $1 trillion in US retail sales by 2030.² Meanwhile, 81%

Phison Launches Purpose-Built Storage Solutions for New Space Economy17.11.2026 16:00:00 EET | Press release

Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of Pascari Space, a new category of purpose-built SSD solutions engineered for commercial outer space applications and orbital infrastructure, on display this week at the SC26 conference. Built upon Phison's decades of NAND engineering expertise and flight-proven storage heritage, Pascari Space leverages Phison IMAGIN+ customization and design services to deliver mission-specific storage solutions built to withstand the extreme demands of outer space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117623865/en/ Phison Launches Purpose-Built Storage Solutions for New Space Economy As terrestrial data infrastructure faces mounting challenges related to power consumption, cooling demands, physical space constraints and natural disaster risks, enterprise and commercial organizations are incr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye